Pharmaceutical Companies in Germany: Market, Regulation, and Setup

What is the size of Germany's pharmaceutical market?

Germany is the largest pharmaceutical market in Europe and the third largest globally, with a market volume of approximately €75 billion in 2023. Germany accounts for roughly 25% of total EU pharmaceutical production by value. The statutory health insurance (GKV) system provides mandatory reimbursement for prescription medicines, underpinning strong and stable market demand.

What licence is required to manufacture medicines in Germany?

Any company manufacturing, importing, or releasing medicinal products in Germany must hold a Herstellungserlaubnis (manufacturing licence) under §13 AMG. The licence is issued by the competent Landesbehörde (state authority) following a GMP inspection. A Sachkundige Person (Qualified Person, §15 AMG) must be appointed and is personally responsible for certifying each batch before release to market.

What is the BfArM and what does it regulate?

The BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, headquartered in Bonn) is Germany's national medicines regulatory authority. It handles national marketing authorisation applications, co-ordinates mutual recognition and decentralised procedures for Germany as reference or concerned member state, oversees pharmacovigilance, controls narcotics under BtMG, and can reclassify products as Arzneimittel. The Paul-Ehrlich-Institut (PEI) handles vaccines, blood products, and ATMPs.

What is AMNOG and how does it affect pharmaceutical pricing?

AMNOG (Arzneimittelmarktneuordnungsgesetz), implemented via §35a SGB V, requires all new prescription medicines entering GKV reimbursement to undergo an early benefit assessment (Nutzenbewertung) by the G-BA within three months of launch. If the G-BA confirms added benefit (Zusatznutzen), the GKV-Spitzenverband negotiates a reimbursement price with the manufacturer. Without confirmed benefit, the medicine is priced within an existing Festbetragsgruppe reference price group.

What is the difference between the EMA and BfArM for drug approval?

The EMA (European Medicines Agency) handles the centralised procedure, resulting in a single EU-wide marketing authorisation — mandatory for biologics, ATMPs, oncology, HIV/AIDS, diabetes, and neurodegenerative drugs. The BfArM handles Germany's national procedure (single-country authorisation), serves as Reference Member State in mutual recognition procedures, and acts as Germany's concerned member state in decentralised procedures involving multiple EU countries.

Are pharmacy chains allowed in Germany?

No. Under §8 ApoG, pharmacy ownership in Germany is restricted to individual approbierte Apotheker (licensed pharmacists). Corporate pharmacy chains are prohibited. A pharmacist may own up to four pharmacy locations (Hauptapotheke plus up to three Filialen) under §2 ApoG. This fremd- und mehrbesitzverbot (prohibition on third-party and multi-ownership) is a longstanding feature of German pharmacy law upheld by the Federal Constitutional Court.

What GMP standards apply to pharmaceutical manufacturers in Germany?

Pharmaceutical manufacturers in Germany must comply with EU GMP as set out in EU Directive 2001/83/EC and EudraLex Volume 4 (Parts I, II, and III). The German implementing regulation is the AMWHV (Arzneimittel- und Wirkstoffherstellungsverordnung). GMP inspections are conducted by the Landesbehörde typically every two to three years. API manufacturers supplying EU-authorised products must be listed in the EudraGMDP database.

What is the Paul-Ehrlich-Institut and what does it regulate?

The Paul-Ehrlich-Institut (PEI), based in Langen near Frankfurt, is the German federal authority responsible for vaccines, blood and plasma products, allergen preparations, and Advanced Therapy Medicinal Products (ATMPs). It assesses batch release applications, conducts clinical trial authorisations for these product categories, and represents Germany at the EMA's Committee for Advanced Therapies (CAT). The PEI is distinct from the BfArM, which covers conventional small-molecule drugs and medical devices.

How do clinical trials work in Germany under the EU CTR?

Since January 2023, all clinical trials with medicinal products in the EU — including Germany — are governed by EU Clinical Trials Regulation 536/2014. Sponsors submit applications via the CTIS (Clinical Trials Information System) portal. In Germany, both BfArM authorisation and a positive opinion from a recognised Ethikkommission are required before trial commencement. GCP compliance (ICH E6(R2)) is mandatory. For academic research, BMBF funds trials via the KKS network of coordinating centres.

What is an ATMP and how are they regulated in Germany?

ATMPs (Advanced Therapy Medicinal Products) include gene therapies, somatic cell therapies, and tissue-engineered products, regulated under EU Regulation 1394/2007. They require mandatory EMA centralised marketing authorisation. In Germany, the Paul-Ehrlich-Institut (PEI) is the competent authority for ATMP clinical trial authorisations. The §4b AMG hospital exemption allows hospitals to manufacture individualised, non-routine ATMPs for specific patients without full marketing authorisation, subject to Landesbehörde oversight.

What is Apothekenpflicht in German pharmaceutical law?

Apothekenpflicht means that prescription medicines and many non-prescription (OTC) products in Germany may only be dispensed through licensed pharmacies (Apotheken). The specific list of apothekenpflichtige Arzneimittel is defined under §43 AMG. Exceptions include certain OTC products that are also freiverkäuflich (sold freely in drugstores and supermarkets). Online pharmacy sales are permitted for non-prescription medicines via EU-registered online pharmacies under the EU Falsified Medicines Directive framework.

What are the main pharma industry associations in Germany?

The three main associations are: VFA (Verband Forschender Arzneimittelhersteller) representing research-based multinational companies including Bayer, Merck KGaA, Pfizer Germany, and Roche Germany; BAH (Bundesverband der Arzneimittel-Hersteller) representing 400+ OTC and self-medication manufacturers; and ProGenerika representing generic and biosimilar manufacturers. The vfa-bio section covers biotechnology and biosimilar interests within the VFA umbrella.

What does §2 AMG define as a medicinal product (Arzneimittel)?

§2 AMG defines an Arzneimittel as any substance or preparation intended to treat, prevent, diagnose, alleviate, or cure disease in humans or animals — or to restore, improve, or influence physiological functions — through pharmacological, immunological, or metabolic means. This functional definition means that even a product not explicitly marketed as a medicine can be classified as an Arzneimittel by the BfArM if it meets the criteria, triggering full AMG compliance requirements.

What is the Betriebserlaubnis for a pharma manufacturer and how does it differ from the Herstellungserlaubnis?

The Herstellungserlaubnis under §13 AMG is the manufacturing licence required for producing or releasing medicinal products. A Betriebserlaubnis (operating permit) refers to the broader facility approval that may also encompass warehousing, wholesale, and import activities under §52a AMG (wholesale distribution). A pharma company distributing but not manufacturing medicines requires a Großhandelserlaubnis under §52a AMG issued by the Landesbehörde, separate from the §13 manufacturing licence.

Can a foreign company establish a pharmaceutical business in Germany?

Yes. EU and non-EU companies may establish a German pharmaceutical subsidiary (typically a GmbH) and apply for the necessary licences from the Landesbehörde and BfArM. Non-EU companies must appoint a EU-based Qualified Person (§15 AMG) who is resident in the EU and may be German or from any EU member state. The German entity must meet full AMG, AMWHV, and GMP requirements — there is no simplified pathway for foreign-owned manufacturers.